Hospital Acquired Infection Control Market Size, Share & Global Report 2030

Global Hospital Acquired Infection Control Market Size and Share

Market Overview

Study Period	2019 - 2030
Market Size (2025)	USD 4.43 Billion
Market Size (2030)	USD 5.38 Billion
Growth Rate (2025 - 2030)	3.97% CAGR
Fastest Growing Market	Asia Pacific
Largest Market	North America
Market Concentration	Low
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Global Hospital Acquired Infection Control Market (2025 - 2030) — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Global Hospital Acquired Infection Control Market Analysis by Mordor Intelligence

The Global Hospital Acquired Infection Control Market size is estimated at USD 4.43 billion in 2025, and is expected to reach USD 5.38 billion by 2030, at a CAGR of 3.97% during the forecast period (2025-2030).

Demand is being driven by mandatory infection-reporting rules, expanding surgical volumes, and the growing financial penalties tied to high infection rates. Hospitals are broadening prevention programs to cover the entire patient pathway, which is lifting purchases of both single-use supplies and outsourced service contracts. UV-C robots, hydrogen-peroxide sterilizers, and data-rich hand-hygiene trackers are moving from pilot projects to routine procurement, encouraged by evidence of double-digit reductions in infection incidence. Vendors are also responding to litigation risk in markets like Australia by supplying traceable, audit-ready processes that help facilities prove compliance.

Ket Report Takeaways

By type, consumables led with 46.57% of hospital-acquired infection control market share in 2024, while services are projected to expand at a 5.25% CAGR to 2030.
By end-user, hospitals and ICUs commanded 62.77% of the hospital-acquired infection control market size in 2024; ambulatory surgical centers are advancing at a 6.05% CAGR through 2030.
By infection type, surgical site infections accounted for a 29.13% share of the hospital-acquired infection control market size in 2024, whereas CLABSI prevention is set to grow at a 6.98% CAGR between 2025 and 2030.
By geography, North America held 39.50% of hospital-acquired infection control market share in 2024; Asia-Pacific is on track for a 6.77% CAGR to 2030.

Global Hospital Acquired Infection Control Market Trends and Insights

Driver Impact Analysis

Driver	~% Impact on CAGR	Geographic Relevance	Peak Impact
Rising Surgical Volumes and ICU Admissions	~+1.2%	Global, with emphasis on North America & Europe	Medium term (~ 3-4 yrs)
Mandatory Reporting of HAIs in U.S. & Select EU Nations	~+0.8%	North America & EU	Short term (≤ 2 yrs)
Rise in the Incidences of Different Types of Hospital Acquired Infections	~+1.0%	Global	Medium term (~ 3-4 yrs)
Innovative Technologies Implemented in Devices that Control Infection	~+1.5%	North America, Europe, developed APAC	Long term (≥ 5 yrs)
Rapid Expansion of Ambulatory Surgery Centers in North America	~+0.6%	North America	Medium term (~ 3-4 yrs)
Growing Adoption of Low-temperature H₂O₂ Sterilizers in Europe	~+0.4%	Europe	Short term (≤ 2 yrs)

Source: Mordor Intelligence

Rising Surgical Volumes and ICU Admissions Drive Prevention Needs

Surgical caseloads are climbing with aging populations and improved access to elective procedures. Roughly 1 in 31 inpatients acquires at least one infection each day, lengthening stays by 17 days and prompting a 42% readmission rate within 30 days. The financial impact is acute: surgical site infections alone cost USD 3 billion to USD 5 billion annually. These pressures reinforce continuous purchasing of disinfectants, sterile wraps, and barrier devices across the hospital-acquired infection control market.

Mandatory Reporting Requirements Reshape Compliance Landscape

The United States and several EU states tie Medicare, Medicaid, or national reimbursement to demonstrated infection-control performance, compelling hospitals to fund robust surveillance programs ^{[1]Centers for Disease Control and Prevention, “CDC's Core Infection Prevention and Control Practices for Safe Healthcare Delivery in All Settings,” cdc.gov}.Electronic dashboards that map hand-hygiene events or track central-line days help facilities defend payments and avoid penalties, stimulating demand for data-enabled solutions within the hospital-acquired infection control market.

Rise in Incidences of Different Types of Hospital-Acquired Infections

Central-line infections average 41,000 cases per year in the United States, while catheter-associated UTIs reach 500,000 cases. Preventive measures such as antimicrobial catheters and disinfecting access caps are seeing rapid adoption, reflected in segment growth that outpaces the overall hospital-acquired infection control market.

Innovative Technologies Transform Infection Control Landscape

UV-C disinfection robots can remove 99.9% of pathogens in 10 minutes, with studies showing a 30% decrease in overall infection rates after rollout. AI-driven analytics platforms flag potential outbreaks and guide antibiotic selection, enhancing stewardship efforts. These technologies lower labor demands and strengthen audit trails, positioning them as key growth catalysts.

Restraint Impact Analysis

Restraint	~% Impact on CAGR	Geographic Relevance	Peak Impact
Lack of Awareness Regarding Hospital Acquired Infection	~-0.7%	Emerging markets, rural healthcare settings globally	Medium term (~ 3-4 yrs)
Stringent Regulatory Requirement	~-0.9%	Global, with highest impact in North America & Europe	Short term (≤ 2 yrs)
High Capital Cost of UV/HPV Disinfection Systems for Tier-2 Hospitals	~-1.1%	Emerging markets, smaller hospitals globally	Medium term (~ 3-4 yrs)
Workforce Skill Gaps in Endoscope Reprocessing	~-0.6%	Global, with emphasis on regions with rapid healthcare expansion	Long term (≥ 5 yrs)

Source: Mordor Intelligence

Lack of Awareness Regarding Hospital-Acquired Infection

Many frontline staff still fall short of the WHO’s five-moment hand-hygiene protocol. Ecolab’s electronic monitoring system creates a virtual patient zone and delivers real-time reminders, lifting compliance and providing measurable returns. Yet adoption unevenness continues to dampen the hospital-acquired infection control market.

Stringent Regulatory Requirements Create Market Barriers

Validation studies, sterility assurance audits, and clinical-evidence dossiers extend product launch timelines. The EU MDR demands expanded post-market surveillance, while FDA guidance for high-level disinfectants requires multi-cycle microbiological testing. Smaller firms struggle with capital and expertise, limiting new-entrant flow and tempering growth in the hospital-acquired infection control market.

Hospital Acquired Infection Control Market - Segmental Analysis

By Product: Consumables Lead While Services Gain Momentum

Consumables accounted for 46.57% of hospital-acquired infection control market share in 2024, supported by daily use of disinfectants, sterile drapes, gloves, and wrap materials. The segment delivers predictable volume thanks to mandatory single-use policies and frequent product turn-over. Suppliers are adding color-coded packaging and QR-enabled traceability to help hospitals document compliance. The hospital-acquired infection control market size tied to consumables is expected to post steady mid-single-digit expansion in line with surgical procedure growth.

Services are projected to register a 5.25% CAGR from 2025 to 2030. Hospitals are outsourcing infection-prevention audits, staff training, and sterilizer maintenance to specialists who guarantee performance under outcome-based contracts. Digital dashboards that track infection metrics in real time underpin these offerings. This consultative approach differentiates providers and unlocks recurring revenue streams inside the hospital-acquired infection control market.

By End-User: Hospitals & ICUs Maintain Dominance as ASCs Gain Ground

Hospitals and intensive care units held 62.77% of hospital-acquired infection control market size in 2024, reflecting their high patient density and invasive-procedure mix. Infection-control teams in tertiary centers maintain sophisticated surveillance networks that drive steady procurement of PPE, biocidal agents, and tracking software. The push to eliminate ventilator-associated pneumonia and central-line infections keeps capital budgets intact for new automation systems.

Ambulatory surgical centers are growing at a 6.05% CAGR through 2030. Evidence shows ASC infection rates are about six times lower than hospital outpatient departments. Their reputation for cleanliness draws payers and patients, encouraging investment in point-of-use sterilizers and low-temperature reprocessors that fit compact footprints. As payers shift more elective procedures to outpatient settings, ASCs will represent a rising slice of the hospital-acquired infection control market.

By Infection Type: Surgical Site Infections Drive Market While CLABSI Prevention Accelerates

Surgical site infections accounted for a 29.13% share of hospital-acquired infection control market size in 2024. Their sizable clinical burden keeps antiseptic preps, antimicrobial drapes, and wound-closure technologies in high demand. Institutions are also adding prophylactic antibiotic-impregnated sutures and advanced incision protectors to protocols, reinforcing consumable throughput in the hospital-acquired infection control market.

CLABSI prevention is forecast to climb at a 6.98% CAGR. Disinfecting caps, antimicrobial lock solutions, and training modules for central-line insertion bundles are penetrating care workflows ^{2Source: National Center for Biotechnology Information, “Disinfecting Caps Reduce CLABSI Rates,” ncbi.nlm.nih.gov}. Vendors that integrate catheter materials with digital reminder systems are well placed to capture this fast-growing pocket of the hospital-acquired infection control market.

Geographical Analysis

North America contributed 39.50% of hospital-acquired infection control market share in 2024. CMS reimbursement rules require documented infection-prevention plans cms.gov, while CDC guidelines provide detailed clinical roadmaps. Hospitals respond by funding UV-C robots and real-time location systems that verify protocol adherence. These spending patterns underscore the region’s leading role in the hospital-acquired infection control market.

Europe follows with strong adoption in Germany, France, and the United Kingdom. Although the EU Medical Device Regulation has tightened evidence thresholds, national health services still finance large-scale sterilizer replacements and automated endoscope reprocessors. Informal divergence in infection-control standards complicates procurement but also drives consulting demand as hospitals seek to reconcile local and EU-wide rules. Vendors that can navigate multi-country compliance secure a durable advantage in the hospital-acquired infection control market.

Asia-Pacific is the fastest-growing region at 6.77% CAGR. A pooled infection prevalence of 9.0% across Southeast Asian facilities reveals significant unmet need. Rapid expansion of private hospitals in China and India, together with aging demographics, is accelerating orders for sterilizers, isolation consumables, and hand-hygiene dispensers. Government grants are emerging for rural clinics to adopt low-temperature sterilization, widening the addressable base of the hospital-acquired infection control market.

Latin America and the Middle East & Africa remain smaller contributors but post steady gains as accreditation bodies adopt Joint Commission-style benchmarks. Regional distributors increasingly partner with global OEMs to assemble consumable kits locally, improving affordability and compliance reporting.

Competitive Landscape

The hospital-acquired infection control market features a blend of diversified giants and focused innovators. 3M, STERIS, Getinge, and Ecolab leverage scale, multi-category portfolios, and direct service networks to secure long-term supply contracts. Getinge’s 2025 acquisition of Healthmark Industries strengthened its sterile processing lineup and deepened distribution reach in the United States. Ecolab, after divesting its surgical solutions unit, is concentrating on digital hand-hygiene monitoring and instrument reprocessing assets.

Innovation remains a prime differentiator. STERIS’s integrated capital-plus-consumable bundles promise validated cycle outcomes and remote diagnostics sec.gov. Bactiguard’s antimicrobial endotracheal tube cut ventilator-associated pneumonia incidence in peer-reviewed studies. UV-C robot specialists deploy leasing models that lower capital hurdles, allowing mid-tier hospitals to adopt automation quickly.

Price competition is moderate because regulatory approval and clinician validation erect barriers. Service quality, uptime guarantees, and user-training programs often outweigh pure product cost considerations. Players that combine evidence-backed efficacy with workflow analytics are well placed to enlarge share in the hospital-acquired infection control market.

Global Hospital Acquired Infection Control Industry Leaders

3M Company
Steris PLC
Getinge AB
Ecolab Inc.
Advanced Sterilization Products (Fortive)
*Disclaimer: Major Players sorted in no particular order

Hospital Acquired Infection Control Market Concentration — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Need More Details on Market Players and Competitors?

Download PDF

Recent Industry Developments

January 2025: Getinge completed the acquisition of Healthmark Industries, expanding its infection control consumables portfolio and reinforcing its U.S. distribution network.
January 2025: The American Hospital Association released its 2025 Environmental Scan, highlighting demographic and climate trends likely to influence infection-control strategies.
April 2024: Getinge introduced the Aquadis Index washer-disinfector to boost throughput and traceability in CSSDs
March 2024: The CDC issued revised clinical guidance for C. difficile prevention in acute-care facilities, advocating isolation protocols and antibiotic stewardship.

Table of Contents for Global Hospital Acquired Infection Control Industry Report

1. Introduction

1.1 Study Assumptions & Market Definition
1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

4.1 Market Overview
4.2 Market Drivers
- 4.2.1 Rising Surgical Volumes and ICU Admissions
- 4.2.2 Mandatory Reporting of HAIs in U.S. & Select EU Nations
- 4.2.3 Rise in the Incidences of Different Types of Hospital Acquired Infections
- 4.2.4 Innovative Technologies Implemented in Devices that Control Infection
- 4.2.5 Rapid Expansion of Ambulatory Surgery Centers in North America
- 4.2.6 Growing Adoption of Low-temperature H₂O₂ Sterilizers in Europe
4.3 Market Restraints
- 4.3.1 Lack of Awareness Regarding Hospital Acquired Infection
- 4.3.2 Stringent Regulatory Requirement
- 4.3.3 High Capital Cost of UV/HPV Disinfection Systems for Tier-2 Hospitals
- 4.3.4 Workforce Skill Gaps in Endoscope Reprocessing
4.4 Supply-Chain Analysis
4.5 Technological Outlook
4.6 Porters Five Forces
- 4.6.1 Threat of New Entrants
- 4.6.2 Bargaining Power of Buyers
- 4.6.3 Bargaining Power of Suppliers
- 4.6.4 Threat of Substitutes
- 4.6.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

5.1 By Product and Services
- 5.1.1 By Equipment
- 5.1.1.1 Sterilization
- 5.1.1.1.1 Steam Sterilizers
- 5.1.1.1.2 Low-temperature Hâ‚‚Oâ‚‚ Sterilizers
- 5.1.1.1.3 Ethylene Oxide Sterilizers
- 5.1.1.1.4 Radiation Sterilization
- 5.1.1.1.5 Contract Sterilization Services
- 5.1.1.2 Disinfection
- 5.1.1.2.1 UV & Hydrogen-Peroxide-Vapor Devices
- 5.1.1.2.2 Endoscopic Reprocessor Systems
- 5.1.1.3 Others
- 5.1.2 Services
- 5.1.3 Consumables
5.2 By End-user
- 5.2.1 Hospitals & Intensive Care Units (ICUs)
- 5.2.2 Ambulatory Surgical Centers (ASCs)
- 5.2.3 Long-term Care Facilities
- 5.2.4 Specialty Clinics & Dialysis Centers
5.3 By Infection Type
- 5.3.1 Surgical Site Infections (SSI)
- 5.3.2 Catheter-associated Urinary Tract Infections (CAUTI)
- 5.3.3 Central-line Associated Bloodstream Infections (CLABSI)
- 5.3.4 Hospital-acquired & Ventilator-associated Pneumonia (HAP/VAP)
- 5.3.5 Gastro-intestinal Infections & Others
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America

6. Competitive Landscape

6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
- 6.3.1 Dentsply Sirono
- 6.3.2 3M Company
- 6.3.3 Steris PLC
- 6.3.4 Getinge AB
- 6.3.5 Ecolab Inc.
- 6.3.6 Advanced Sterilization Products
- 6.3.7 Steris
- 6.3.8 Belimed AG
- 6.3.9 Becton, Dickinson and Company
- 6.3.10 Olympus Corporation
- 6.3.11 Matachana Group
- 6.3.12 MMM Group
- 6.3.13 Cardinal Health Inc.
- 6.3.14 Halyard Health
- 6.3.15 Ansell Limited
- 6.3.16 Metrex Research (Envista)
- 6.3.17 HuFriedyGroup
- 6.3.18 GAMA Healthcare
- 6.3.19 Medline Industries
- 6.3.20 Steelco S.p.A.
- 6.3.21 Fedegari Autoclavi S.p.A.
- 6.3.22 Tuttnauer

7. Market Opportunities & Future Outlook

7.1 White-space & Unmet-need Assessment

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections

Get Price Break-up Now

Global Hospital Acquired Infection Control Market Report Scope

As per the scope of the report, hospital-acquired infections are also nosocomial infections developed in hospitals and other healthcare facilities. These infections can occur up to 48 hours after hospital admission, up to three days after discharge, up to 30 days after an operation, or in a healthcare facility when the patient was admitted for reasons other than an infection. The hospital-acquired infection control market is segmented by equipment, end user, infection type, and geography. By equipment, the market is segmented into sterilization, services, and consumables. By end-users, the market is segmented into hospitals & intensive care units (ICUs), ambulatory surgical centers (ASCs), long-term care facilities, and specialty clinics & dialysis centers. By infection type, the market is segmented into surgical site infections (SSI), catheter-associated urinary tract infections (CAUTI), central-line bloodstream infections (CLABSI), hospital-acquired & ventilator-associated pneumonia (HAP/VAP) and gastrointestinal infections & others. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (in USD million) for the above segments.

By Product and Services	By Equipment	Sterilization	Steam Sterilizers
			Low-temperature Hâ‚‚Oâ‚‚ Sterilizers
			Ethylene Oxide Sterilizers
			Radiation Sterilization
			Contract Sterilization Services

		Disinfection	UV & Hydrogen-Peroxide-Vapor Devices
			Endoscopic Reprocessor Systems
		Others
	Services
	Consumables
By End-user	Hospitals & Intensive Care Units (ICUs)
	Ambulatory Surgical Centers (ASCs)
	Long-term Care Facilities
	Specialty Clinics & Dialysis Centers
By Infection Type	Surgical Site Infections (SSI)
	Catheter-associated Urinary Tract Infections (CAUTI)
	Central-line Associated Bloodstream Infections (CLABSI)
	Hospital-acquired & Ventilator-associated Pneumonia (HAP/VAP)
	Gastro-intestinal Infections & Others

Geography	North America	United States
		Canada
		Mexico

	Europe	Germany
		United Kingdom
		France
		Italy
		Spain
		Rest of Europe

	Asia-Pacific	China
		Japan
		India
		Australia
		South Korea
		Rest of Asia-Pacific

	Middle East and Africa	GCC
		South Africa
		Rest of Middle East and Africa

	South America	Brazil
		Argentina
		Rest of South America

By Product and Services

By Equipment	Sterilization	Steam Sterilizers
		Low-temperature Hâ‚‚Oâ‚‚ Sterilizers
		Ethylene Oxide Sterilizers
		Radiation Sterilization
		Contract Sterilization Services

	Disinfection	UV & Hydrogen-Peroxide-Vapor Devices
		Endoscopic Reprocessor Systems
	Others
Services
Consumables

By End-user

Hospitals & Intensive Care Units (ICUs)

Ambulatory Surgical Centers (ASCs)

Long-term Care Facilities

Specialty Clinics & Dialysis Centers

By Infection Type

Surgical Site Infections (SSI)

Catheter-associated Urinary Tract Infections (CAUTI)

Central-line Associated Bloodstream Infections (CLABSI)

Hospital-acquired & Ventilator-associated Pneumonia (HAP/VAP)

Gastro-intestinal Infections & Others

Geography

North America	United States
	Canada
	Mexico
Europe	Germany
	United Kingdom
	France
	Italy
	Spain
	Rest of Europe
Asia-Pacific	China
	Japan
	India
	Australia
	South Korea
	Rest of Asia-Pacific
Middle East and Africa	GCC
	South Africa
	Rest of Middle East and Africa
South America	Brazil
	Argentina
	Rest of South America

Need A Different Region or Segment?

Customize Now

Key Questions Answered in the Report

What is the current value of the hospital-acquired infection control market?

The market stands at USD 4.43 billion in 2025 and is projected to reach USD 5.38 billion by 2030.

Which product segment leads the hospital-acquired infection control market?

Consumables lead with 46.57% market share thanks to daily demand for disinfectants, wraps, and PPE.

Why are ambulatory surgical centers attracting attention in infection control?

They record infection rates about six times lower than hospital outpatient departments, driving a 6.05% CAGR for related solutions.

How are UV-C robots impacting infection rates?

Studies show these robots can cut overall healthcare-associated infections by 30% after deployment.

Which region is growing fastest in the hospital-acquired infection control market?

Asia-Pacific is advancing at a 6.77% CAGR due to hospital construction, rising surgical volumes, and stronger awareness campaigns.

What regulatory factors influence purchasing decisions in North America?

CMS reimbursement conditions and CDC guidelines require hospitals to document infection-control performance, motivating investment in validated technologies.